HK1254608A1 - 改良的地拉罗司制剂及其制备方法 - Google Patents

改良的地拉罗司制剂及其制备方法 Download PDF

Info

Publication number
HK1254608A1
HK1254608A1 HK18113574.7A HK18113574A HK1254608A1 HK 1254608 A1 HK1254608 A1 HK 1254608A1 HK 18113574 A HK18113574 A HK 18113574A HK 1254608 A1 HK1254608 A1 HK 1254608A1
Authority
HK
Hong Kong
Prior art keywords
methods
same
deferasirox
making
improved formulations
Prior art date
Application number
HK18113574.7A
Other languages
English (en)
Chinese (zh)
Inventor
Dave A. Miller
Justin M. Keen
Sandra U. KUCERA
Original Assignee
Dispersol Technologies, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dispersol Technologies, Llc filed Critical Dispersol Technologies, Llc
Publication of HK1254608A1 publication Critical patent/HK1254608A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18113574.7A 2015-06-17 2016-06-17 改良的地拉罗司制剂及其制备方法 HK1254608A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562180998P 2015-06-17 2015-06-17
US62/180,998 2015-06-17
PCT/US2016/038089 WO2016205658A1 (en) 2015-06-17 2016-06-17 Improved formulations of deferasirox and methods of making the same

Publications (1)

Publication Number Publication Date
HK1254608A1 true HK1254608A1 (zh) 2019-07-26

Family

ID=57546755

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18113574.7A HK1254608A1 (zh) 2015-06-17 2016-06-17 改良的地拉罗司制剂及其制备方法

Country Status (10)

Country Link
US (4) US10265301B2 (cg-RX-API-DMAC7.html)
EP (1) EP3310354B1 (cg-RX-API-DMAC7.html)
JP (1) JP2018517734A (cg-RX-API-DMAC7.html)
CN (1) CN107847490A (cg-RX-API-DMAC7.html)
AU (3) AU2016280280B2 (cg-RX-API-DMAC7.html)
CA (1) CA2989145C (cg-RX-API-DMAC7.html)
HK (1) HK1254608A1 (cg-RX-API-DMAC7.html)
IL (1) IL256322B (cg-RX-API-DMAC7.html)
MA (1) MA43271A (cg-RX-API-DMAC7.html)
WO (1) WO2016205658A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103290106B (zh) 2007-12-05 2015-07-29 考利达基因组股份有限公司 测序反应中碱基的有效确定
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
CN102459592B (zh) 2009-06-15 2017-04-05 考利达基因组股份有限公司 用于长片段阅读测序的方法和组合物
US10837879B2 (en) 2011-11-02 2020-11-17 Complete Genomics, Inc. Treatment for stabilizing nucleic acid arrays
CZ2017255A3 (cs) * 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
WO2019094688A1 (en) * 2017-11-10 2019-05-16 Dispersol Technologies, Llc Improved drug formulations
WO2020061474A1 (en) * 2018-09-20 2020-03-26 Tautona Group Ip Holding Company, L.L.C. Iron chelating compounds for treating aesthetic skin conditions
IL295007A (en) 2020-01-31 2022-09-01 Nanocopoeia Llc Amorphous nilotinib microparticles and uses thereof
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN112870361A (zh) * 2021-01-28 2021-06-01 重庆医科大学 铁死亡抑制剂在制备预防或治疗铁过载导致的骨质疏松或骨丢失的药物中的应用
CN114994205B (zh) * 2022-05-30 2023-03-28 上海奥科达医药科技股份有限公司 地拉罗司颗粒剂中相关杂质的检测方法
AU2025207356A1 (en) 2024-01-11 2026-08-06 Minneamrita Therapeutics Llc Triptolide formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009056D0 (en) * 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
NZ567155A (en) * 2005-10-19 2010-06-25 Novartis Ag Dispersible tablets comprising deferasirox
WO2009026461A2 (en) * 2007-08-21 2009-02-26 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
EP2062572A1 (en) * 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions
EP2291360A2 (en) * 2008-04-21 2011-03-09 Actavis Group PTC ehf. Solid state forms of deferasirox salts and process for the preparation thereof
BR112012013710A2 (pt) * 2009-12-07 2015-09-15 Mapi Pharma Ltd processos para a preparação de deferasirox e polimorfos de deferasirox.
CA2805568A1 (en) 2010-07-08 2012-01-12 Ratiopharm Gmbh Oral dosage form of deferasirox
WO2012025935A2 (en) * 2010-08-25 2012-03-01 Ramamohan Rao Davuluri A process for the preparation of 2-(2-hydroxyphenyl)-benz[1,3]oxazin-4-one and its use for preparation of 4-[3, 5-bis (2-hydroxyphenyl)-1h-1, 2, 4-triazol-1-yl] benzoic acid
PE20140166A1 (es) 2010-10-01 2014-02-17 Cipla Ltd Composicion farmaceutica que comprende deferasirox
US20140039031A1 (en) * 2011-02-23 2014-02-06 Dispersol Technologies. LLC Pharmaceutical formulations of acetyl-11-keto-b-boswellic acid, diindolylmethane, and curcumin for pharmaceutical applications
HUE036921T2 (hu) 2013-03-08 2018-08-28 Novartis Ag Orális deferasirox készítmények
RU2015149544A (ru) 2013-05-10 2017-06-16 Сипла Лимитед Низкодозовая фармацевтическая композиция

Also Published As

Publication number Publication date
AU2016280280B2 (en) 2021-09-02
US10265301B2 (en) 2019-04-23
EP3310354B1 (en) 2026-02-25
AU2021277731A1 (en) 2021-12-23
US20240091201A1 (en) 2024-03-21
IL256322A (en) 2018-02-28
US11878005B2 (en) 2024-01-23
CN107847490A (zh) 2018-03-27
EP3310354A1 (en) 2018-04-25
US20190167643A1 (en) 2019-06-06
AU2024202528B2 (en) 2026-01-08
MA43271A (fr) 2018-09-26
AU2016280280A1 (en) 2018-01-04
WO2016205658A1 (en) 2016-12-22
US20170027911A1 (en) 2017-02-02
US20170296514A1 (en) 2017-10-19
IL256322B (en) 2022-03-01
EP3310354C0 (en) 2026-02-25
AU2024202528A1 (en) 2024-05-09
EP3310354A4 (en) 2018-12-12
CA2989145A1 (en) 2016-12-22
JP2018517734A (ja) 2018-07-05
AU2021277731B2 (en) 2024-04-11
CA2989145C (en) 2024-10-29
US10258608B2 (en) 2019-04-16

Similar Documents

Publication Publication Date Title
CA3287905A1 (en) Compositions, cell constructs, and methods of making and using the same
HK1246800A1 (zh) 用於营养组合物的寡糖组合物和其制造方法
EP3270694A4 (en) Certain chemical entities, compositions, and methods
EP3221391A4 (en) Swellable compositions, articles formed therefrom, and methods of manufacture thereof
CA3285555A1 (en) Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
HK1255162A1 (zh) 爱帕琳肽受体激动剂及使用方法
EP3216030A4 (en) Compositions for compounding, extrusion and melt processing of foamable and cellular halogen-free polymers
WO2014039903A3 (en) Stable aqueous formulations of adalimumab
WO2013177419A3 (en) Lipid nanoparticle compositions and methods of making and methods of using the same
EP3356470B8 (en) Polycarbonate-polysiloxane copolymer compositions, articles formed therefrom, and methods of manufacture thereof
EP3277820A4 (en) Methods for producing modified red blood cell compositions, compositions and uses thereof
EP3359193A4 (en) NOVEL CARBOHYDRATIC ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
WO2014144295A8 (en) Ceftolozane antibiotic compositions
HK1248069A1 (zh) 去乙酰氧基微管溶素h及其类似物
ZA201807446B (en) Improved drug formulations
EP3342794A4 (en) Plasticizer composition, resin composition, and preparation method for both compositions
HK1223300A1 (zh) 皮质类固醇组合物
EP3312203A4 (en) Method for preparing rubber composition using aminosilane-based terminal modifying agent having functional group introduced therein, and rubber composition prepared thereby
EP3284743A4 (en) Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof
EP3313393A4 (en) Platinum compounds, compositions and uses thereof
EP3260477A4 (en) Composition for polymerization, method for producing same, coating composition containing same, method for producing coating composition containing said compositions, and method for producing coating
EP3606623A4 (en) PROTECTION AND PRODUCTION COMPOSITIONS (PPC)
EP3303320A4 (en) Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same
WO2016033549A3 (en) (17-β)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
EP3378495A4 (en) COMPOSITION WITH NOVEL GLUTAMIC ACID DERIVATIVE AND BLOCK COPOLYMER AND USE THEREOF